Amoxicillin/clavulanic acid: A review of its use in the management of paediatric patients with acute otitis media

Drugs

Volumn 63, Issue 3, 2003, Pages 311-340

  Easton, Jane ^a   Noble, Stuart ^a   Perry, Caroline M ^a   Cuffini, A M ^b   Jacobs, M R ^c   Subba Rao, S D ^d   Pichichero, M E ^e   Thornsberry, C ^f  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f MRL Pharmaceutical Services   (United States)

Author keywords

Acute otitis media; Amoxicillin clavulanic acid; Antibacterial; AOM; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AUGMENTIN ES 600; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; MACROLIDE;

AGE; ALLERGIC VASCULITIS; ANTIBACTERIAL ACTIVITY; CHILDHOOD DISEASE; CLINICAL TRIAL; DIAPER DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; INDIGESTION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; OBSTRUCTIVE JAUNDICE; OTITIS MEDIA; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PSEUDOMEMBRANOUS COLITIS; RASH; REVIEW; SERUM SICKNESS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TOXIC EPIDERMAL NECROLYSIS; VOMITING;

ACUTE DISEASE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CHILD; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; OTITIS MEDIA;

HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037278556     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363030-00005     Document Type: Review

References (90)

1. Bluestone CD. Otitis media: To treat or not to treat? Consultant 1998; 38 (6): 1421-33
2. Hamer DH. IDCP guidelines: Epiglottitis and otitis. Infect Dis Clin Pract 1997; 6 (8): 500-5
3. Leibovitz E, Dagan R. Antibiotic treatment for acute otitis media. Int J Antimicrob Agents 2000; 15 (3): 169-77
4. Brooke I, Burke P. The management of acute, serous and chronic otitis media: the rol of anaerobic bacteria. J Hosp Infect 1992; 22 Suppl. A: 75-87
5. Brook I, Van de Heyning PH. Microbiology and management of otitis media. Scand J Infect Dis 1994 Suppl. 93: 20-32
6. Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990 Feb; 39 (2): 264-307
7. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999 Jan; 18 (1): 1-9
8. GlaxoSmithKline. Prescribing information for AugmentinR powder for oral suspension and chewable tablets [online]. Available from URL: http://www.augmentin.com [Accessed 2002 Dec 6]
9. GlaxoSmithKline. Prescribing information for AugmentinR tablets [online]. Available from URL: http://www.augmentin.com [Accessed 2002 Dec 6]
10. GlaxoSmithKline. Prescribing information for Augmentin ES-600TM [online]. Available from URL: http://www.augmentin.com/[Accessed 2002 Dec 6]
11. Poole MD. Implications of drug-resistant Streptococcus pneumoniae for otitis media. Pediatr Infect Dis J 1998 Oct; 17 (10): 953-6
12. Mason Jr EO, Lamberth LB, Kershaw NL, et al. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother 2000; 45: 623-31
13. Doern GV, Jones RN, Pfaller MA, et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-aquired respiratory tract infections: antimicrobial susceptibility from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1999 Feb; 43 (2): 385-9
14. Felmingham D, Grüneberg NR, and the Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203
15. Turnak MR, Bandak SI, Bouchillon SK, et al. Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999-2000 from 13 countries. Clin Microbiol Infect 2001 Dec; 7 (12): 671-7
16. Staples AM, Thornsberry C, Critchley IA, et al. Resistance in respiratory tract pathogens in 2000: a worldwide view [abstract no. 1221]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
17. Bandak SI, Turnak MR, Allen BS, et al. Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. Eur J Clin Microbiol Infect Dis 2001; 20: 55-60
18. Brook I, Gober AE. Effect of amoxicillin and co-amoxiclav on the aerobic and anaerobic nasopharyngeal flora. J Antimicrob Chemother 2002; 49: 689-92
19. National Committee for Clinical Laboratory Standards, editor. Performance standards for antimicrobial susceptibility testing: 12th informational supplement. Wayne (Pennsylvania): National Committee for Clinical Laboratory Standards, 2002. Document M100-S12, Vol 22, No. 1
20. Baquero F, García-Rodríguez JA, García de Lomas J, et al. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicentre surveillance study. Antimicrob Agents Chemother 1999 Feb; 43 (2): 357-9
21. Schmitz F-J, Verhoef J, Fluit AC, et al. Comparative activity of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates originating from 20 European university hospitals. Eur J Clin Microbiol Infect Dis 1999; 18: 450-3
22. Richter SS, Brueggemann BA, Huynh KH, et al. A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. Int J Antimicrob Agents 1999; 13: 99-107
23. Liu Y-C, Huang W-K, Cheng D-L. Antibacterial activity of cefpodoxime in vitro. Chemotherapy 1997; 43: 21-6
24. Tubau F, Fernández-Roblas R, Liñares J, et al. In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods. J Antimicrob Chemother 2001; 47: 675-80
25. Fluit AC, Jones ME, Schmitz F-J, et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000 Mar; 30: 454-60
26. Jones EM, Staples AM, Critchley I, et al. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study. Diagn Microbiol Infect Dis 2000; 37: 203-11
27. Zhanel GG, Karlowsky JA, Low DE, et al. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada 1997-1998. J Antimicrob Chemother 2000; 45: 655-62
28. Jones RN, Croco MAT, Kugler KC, et al. Respiratory tract pathogens isolated from patients hospitalised with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 2000; 37: 115-25
29. Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29-33
30. Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999 Jan; 43 (1): 29-34
31. Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999 Jan; 43 (1): 35-40
32. Ponte C, Cenjor C, Parra A, et al. Antimicrobial treatment of an experimental otitis media caused by a beta-lactamase positive isolate of Haemophilus influenzae. J Antimicrob Chemother 1999; 44 (1): 85-90
33. Berry V, Thorburn CE, Knott SJ, et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 1998 Dec; 42 (12): 3193-9
34. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998 Sept; 42 (9): 2375-9
35. Reed MD. The clinical pharmacology of amoxicillin and clavulanic acid. Pediatr Infect Dis J 1998 Oct: 17 (10): 957-62
36. Gálvez-Múgica MA, Frías-Iniesta J, Guerra P, et al. Comparative bioavailability of two oral 875/125mg sachet formulations of amoxicillin/clavutanic acid in healthy volunteers. Clin Drug Invest 1999 Sep; 18 (3): 217-24
37. Sourgens H, Steinbrede H, Verschoor JSC, et al. Bioequivalence study of a novel Solutab (Rm) tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet. Int J Clin Pharmacol Ther 2001 Feb; 39 (2): 75-82
38. Ergün H, Baykara T, Taskin T, et al. Determination of oral bioavailability of Augmentin (RM) (Fako) and Amoklavin (Rm) (Deva) in tablet and oral suspension form in healthy volunteers using a double-blind, cross-over, randomized block design [abstract no. 455]. Eur J Clin Pharmacol 1997; 52 Suppl.: 147
39. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996 Mar; 15 (3): 255-9
40. Fraschini F, Scaglione F, Falchi M, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990 Jun; 2 (3): 171-7
41. Seikel K, Shelton S, McCracken Jr GH. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1998 Jul; 16 (7): 969-70
42. Ginsburg CM, McCracken Jr GH, Nelson JD. Pharmacology of oral antibiotics used for treatment of otitis media and tonsillopharyngitis in infants and children. Ann Otol Rhinol Laryngol 1981; 90 (3) Suppl. III: 37-43
43. Marchant CD, Carlin SA, Johnson CE, et al. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The 'Pollyanna phenomenon'. J Pediatr 1992 Jan; 120 (1): 72-7
44. Dagan R, Leibovitz E, Greenberg D, et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998 Sep; 17 (9): 776-82
45. Carlin SA, Marchant CD, Shurin PA, et al. Host factors and early therapeutic response in acute otitis media. J Pediatr 1991 Feb; 118 (2): 178-83
46. Arguedas A, Loaiza C, Herrera M, et al. Comparative trial of 3-day azithromycin versus 10-day amoxycillin/clavulanate potassium in the treatment of children with acute otitis media with effusion. Int J Antimicrob Agents 1996; 6 (4): 233-8
47. Aronovitz G. A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996; 15 (9) Suppl.: S15-9
48. Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. [erratum appears in Pediatr Infect Dis J 2000 Apr; 19(4):275]. Pediatr Infect Dis J 2000 Feb; 19 (2): 95-104
49. Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 65-71
50. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 1995; 14 (8): 669-76
51. Aspin MM, Hoberman A, McCarty J, et al. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. J Pediatr 1994 Jul; 125 (1): 136-41
52. Gooch WM 3rd, Blair E, Puopolo A, et al. Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion. Clin Ther 1995 Sep-Oct; 17 (5): 838-51
53. McLinn SE, Moskal M, Goldfarb J, et al. Comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions in treatment of acute otitis media with effusion in children. [erratum appears in Antimicrob Agents Chemother 1994 Oct;38(10):2516]. Antimicrob Agents Chemother 1994 Feb; 38 (2): 315-8
54. Pessey JJ, Gehanno P, Thoroddsen E, et al. Short course therapy with cefuroxime axetil for acute otitis media: Results of a randomized multicenter comparison with amoxicillin/clavulanate. Pediatr Infect Dis J 1999 Oct; 18 (10): 854-9
55. Block SL, McCarty JM, Hedrick JA, et al. Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children. Pediatr Infect Dis J 2000; 19 (12 Suppl.): S159-65
56. Gehanno P, Berche P, Boucot I, et al. Comparative efficacy and safety of cefprozil and amoxycillin/clavulanate in the treatment of acute otitis media in children. J Antimicrob Chemother 1994 Jun; 33 (6): 1209-18
57. Gehanno P, Barry B, Bobin S, et al. Twice daily cefpodoxime proxetil compared with thrice daily amoxicillin/clavulanic acid for treatment of acute otitis media in children. Scand J Infect Dis 1994; 26 (5): 577-84
58. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001 Sep; 20 (9): 829-37
59. Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin®) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997 May; 16 (5): 463-70
60. Thornsberry C, Ogilvie PT, Holley Jr HP, et al. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob Agents Chemother 1999 Nov; 43 (11): 2612-23
61. Dietz H, Machka K, Höbel W, et al. Amoxycillin/clavulanic acid in the treatment of acute otitis media in pediatric patients [abstract no. P297]. Clin Microbiol Infect 1999 Mar; 5 Suppl. 3: 164
62. Behre U, Burow H-M, Quinn P, et al. Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children. Infection 1997; 25 (3): 163-6
63. Damrikarnlert L, Jauregui AC, Kzadri M, et al. Efficacy and safety of amoxycillin/clavulanate (Augmentin®) twice daily versus three times daily in the treatment of acute otitis media in children. J Chemother 2000; 12 (1): 79-87
64. McLinn SE, McCarty JM, Perrotta R, et al. Multicenter controlled trial comparing ceftibuten with amoxicillin/clavulanate in the empiric treatment of acute otitis media. Pediatr Infect Dis J 1995 Jul; 14 (7) Suppl.: S108-14
65. Gooch WM 3rd, Philips A, Rhoades R, et al. Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J 1997 Feb; 16 (2) Suppl.: S21-4
66. Roche Pharmaceuticals. Rocephin (ceftriaxone sodium) for injection, complete product information (online). Roche Pharmaceuticals, 2002. Available from URL: http://www.roche usa.com/products/rocephin/pi.html [Accessed 30 Jul 2002]
67. Al-Ghamdi YS, El-Kafrawi M, Aglan YI, et al. Efficacy of single-dose intramuscular ceftriaxone for treatment of acute otitis media in children. Saudi Med J 1999; 20 (1): 41-5
68. Varsano I, Volovitz B, Horev Z, et al. Intramuscular ceftriaxone compared with oral amoxicillin-clavulanate for treatment of acute otitis media in children. Eur J Pediatr 1997 Nov; 156 (11): 858-63
69. Adler M, McDonald PJ, Trostmann U, et al. Cefdinir vs. amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children. Pediatr Infect Dis J 2000 Dec; 19 Suppl. 12: S166-70
70. Subba Rao SD, Macias MP, Dillman CA, et al. A randomised, observer-blind trial of amoxicillin/clavulanate versus cefaclor in the treatment of children with acute otitis media. J Chemother 1998; 10 (6): 460-8
71. Khurana CM. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Pediatr Infect Dis J 1996 Sep; 15 (9) Suppl.: S24-9
72. McLinn S. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J 1996; 15 (9) Suppl.: S20-3
73. Schaad UB. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. J Antimicrob Chemother 1993; 31 Suppl. E: 81-8
74. McCarty JM, Phillips A, Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993 Dec; 12 (12) Suppl.: S122-7
75. Ramet J. A safety and efficacy comparative study of clarithromycin and amoxillin/clavulanate suspensions in the short course treatment of children with acute otitis media. Acta Ther 1995; 21 (3-4): 231-41
76. Bottenfield GW, Burch DJ, Hedrick JA, et al. Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin registered) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1998; 17 (10): 963-8
77. Stein GE, Gurwith MJ. Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. Clin Pharm 1984 Nov-Dec; 3 (6): 591-9
78. Chawla A, Kahn E, Yunis EJ, et al. Rapidly progressive cholestasis: An unusual reaction to amoxicillin/clavulanic acid therapy in a child. J Pediatr 2000 Jan; 136 (1): 121-3
79. Benjamin S, Mueller BA. Erythema multiforme secondary to amoxicillin/clavulanic acid exposure. Ann Pharmacother 1999; 33 (1): 109-10
80. Toscani M, Drehobl M, Freed J, et al. A multicenter, randomized, comparative assessment in healthy pediatric volunteers of the palatability of oral antibiotics effective in the therapy of otitis media. Curr Ther Res Clin Exp 2000 May; 61 (5): 278-85
81. Powers JL, Gooch III WM, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J 2000 Dec; 19 (12) Suppl.: S174-80
82. Pelton SI. New concepts in the pathophysiology and management of middle ear disease in childhood. Drugs 1996; 52 Suppl. 2: 62-7
83. Tarlow. Otitis media: pathogenesis and medical sequelae. Ear, Nose and Throat Journal 1998 June; 77 (6) Suppl.: 3-6
84. Hoberman A, Paradise JL. Acute otitis media: Diagnosis and management in the year 2000. Pediatr Ann 2000; 29 (10): 609-20
85. Jacobs MR. Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: Overview and update. Pediatr Infect Dis J 1998 Oct; 17 (10): 947-52
86. Thornsberry C, Sahm DF. Resistance in respiratory tract pathogens: an international study 1997-1998. J Chemother 2000; 12 Suppl. 4: 16-20
87. Dagan R, Leibovitz E, Cheletz G, et al. Antibiotic treatment in acute otitis media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment. J Infect Dis 2001 Mar 15; 183 (6): 880-6
88. Jacobs MR. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Am J Med 1999 May 3; 106 (5A): 19S-25S
89. Dowell SF, Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Physician 1997 Apr; 55 (5): 1647-54
90. Block SL, Harrison CJ, Hedrick JA, et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J 1995; 14 (9): 751-9